Histogenics Acquires Rights to NeoCart for the Japanese Market

Histogenics acquired development and commercialization rights to NeoCart® for the Japanese market from its development partner Purpose Co. NeoCart autologous cell therapy is designed to treat knee cartilage defects.

Histogenics notes that the Japanese market for cartilage repair is estimated at >200,000 procedures...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0